About HyperMed

HyperMed is developing hyperspectral imaging for medical applications. The technology, originally developed for military surveillance, provides an advanced form of spectroscopy that provides a two-dimensional tissue oxygenation map. The company’s first product, OxyVu, was developed for the US research market and subsequently received FDA 510(k) approval for medical diagnostic applications where the measurement of microvasculature perfusion can assist physicians with patient care. Multiple published studies have demonstrated the clinical utility of OxyVu for the diagnostic assessment of wound healing, diabetic foot ulcers, and amputation planning. The market opportunity for the clinical diagnostic applications for hyperspectral imaging represent a multi-billion market.

website icon
Website
employees icon
Employees
industry icon
Industry
Medical Practices
location icon
Phone number
+2037692349
location icon
Headquarter
Burlington, Massachusetts
description icon
Founded
1997

Frequently Asked Questions about HyperMed

Who is the CEO of HyperMed?

Jean-claude Lemper is the CEO of HyperMed. To contact Jean-claude Lemper email at [email protected].

Who are the decision makers in HyperMed?

The decision makers in HyperMed are David Wetherell, Jean-claude Lemper, Luis Alfredo Perez Bolde Hernande, etc. Click to Find HyperMed decision makers emails.

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.

Discover the source of our data

Learn more